Old drug tested to tame dangerous side effects of Cutting-Edge cancer treatments
NCT ID NCT07169487
Summary
This early-stage study is testing if an existing drug called methylene blue can help control severe side effects that sometimes occur after powerful cancer immunotherapies like CAR-T. The side effects, called CRS and ICANS, involve dangerous immune system overreactions and neurological problems. Researchers will give the drug to a small group of adult patients to find a safe dose and see if it eases these complications without harming the cancer-fighting power of their treatment.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CYTOKINE RELEASE SYNDROME are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Institute of Hematology & Blood Diseases Hospital
RECRUITINGTianjin, Tianjin Municipality, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.